This transcript has been edited for clarity.
Akshay B. Jain, MD: Hi. My name is Dr Akshay Jain, and with me is Dr Harpreet Bajaj. Together, we're the columnists of Medscape's Sugar Beat. We are very excited to discuss highlights of the American Diabetes Association 81st Scientific Sessions, especially the clinically relevant points.
The Incretins
Let me start off with the glucagon-like peptide 1 (GLP-1) studies. The SUSTAIN FORTE study, for which Dr Bajaj was one of the coauthors, was a head-to-head comparison of the glycemic-lowering effect of semaglutide 2.0 mg/wk vs 1.0 mg/wk on the background of metformin plus or minus sulfonylurea therapy.
[Among patients with] a baseline A1c of 8.8%, semaglutide 2.0 mg/wk reduced the A1c by 2.2% vs 1.9% with the lower dose of semaglutide. The weight reduction was about 0.93 kg more with the higher dose. In my opinion, the A1c difference, although statistically significant, may not be too clinically relevant from strictly the glycemic control point of view, although the weight reduction was quite significant.
If the 2-mg dose ever comes out on the market, depending on the cost difference between the two doses, it may be worthwhile to consider a different agent to achieve further glycemic control based on the target for our patients.
COMMENTARY
Top Studies, Highlights From ADA 2021
Harpreet S. Bajaj, MD, MPH; Akshay B. Jain, MD
DisclosuresJuly 09, 2021
This transcript has been edited for clarity.
Akshay B. Jain, MD: Hi. My name is Dr Akshay Jain, and with me is Dr Harpreet Bajaj. Together, we're the columnists of Medscape's Sugar Beat. We are very excited to discuss highlights of the American Diabetes Association 81st Scientific Sessions, especially the clinically relevant points.
The Incretins
Let me start off with the glucagon-like peptide 1 (GLP-1) studies. The SUSTAIN FORTE study, for which Dr Bajaj was one of the coauthors, was a head-to-head comparison of the glycemic-lowering effect of semaglutide 2.0 mg/wk vs 1.0 mg/wk on the background of metformin plus or minus sulfonylurea therapy.
[Among patients with] a baseline A1c of 8.8%, semaglutide 2.0 mg/wk reduced the A1c by 2.2% vs 1.9% with the lower dose of semaglutide. The weight reduction was about 0.93 kg more with the higher dose. In my opinion, the A1c difference, although statistically significant, may not be too clinically relevant from strictly the glycemic control point of view, although the weight reduction was quite significant.
If the 2-mg dose ever comes out on the market, depending on the cost difference between the two doses, it may be worthwhile to consider a different agent to achieve further glycemic control based on the target for our patients.
Medscape Diabetes © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Top Studies, Highlights From ADA 2021 - Medscape - Jul 09, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Authors
Harpreet S. Bajaj, MD, MPH
Research Associate, Department of Endocrinology, Mount Sinai Hospital, Toronto; Endocrinologist; Director, Late Phase Research, LMC Diabetes & Endocrinology, Brampton, Ontario, Canada
Disclosure: Harpreet S. Bajaj, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Novo Nordisk; Eli Lilly
Received income in an amount equal to or greater than $250 from: Novo Nordisk; Eli Lilly
Akshay B. Jain, MD
Clinical Instructor, Department of Endocrinology, University of British Columbia; Endocrinologist, Fraser River Endocrinology, Vancouver, British Columbia, Canada
Disclosure: Akshay B. Jain, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or member of a speakers bureau for: Abbott; Amgen; Boehringer-Ingelheim; Dexcom; Eli Lilly; Janssen; Medtronic; Merck; Novo Nordisk
Received research grant from: Novo Nordisk
Received an income in an amount equal to or greater than $250 from: Abbott; Amgen; Boehringer-Ingelheim; Dexcom; Eli Lilly; Janssen; Medtronic; Merck; Novo Nordisk